Trial Profile
Effect of sorafenib as second line treatment in patients with metastatic renal cell carcinoma
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 01 Sep 2015
Price :
$35
*
At a glance
- Drugs Sorafenib (Primary)
- Indications Renal cell carcinoma
- Focus Therapeutic Use
- 01 Sep 2015 New trial record